San Raffaele is a Scientific Institute of Hospitalisation and Care and a University Hospital of international importance and high specialisation. It is a place that combines high-tech, state-of-the-art care and a multidisciplinary approach.

The San Raffaele University and Research Hospital, represented by Marco Catucci, won the Start-Up Slams award for the most promising technology for their CAR/TCR T Cell therapy project. This award was a unique opportunity for the project:

“It was an honour to present the CAR-T cell therapy developed by our institute here in this really important event. I think that this event and the pitch give me the possibility to promote this project and to make it visible to very important pharmaceutical companies that I hope will be interested in licensing this technology”.

Tuesday, December 3rd, 2024 | 11.15 am – 12.30 pm
Pharma M&As are back, what does it mean for early-stage dealmaking?

While deal volumes have slowed in recent years, in line with overall M&A activity, deals in the life sciences sector appeared to be picking up slightly at the end of 2023. In 2024, lower valuations are expected to provide pharmaceutical companies with additional transaction and acquisition opportunities at a later stage to strengthen portfolios in the face of impending patent expiry, and at an earlier stage as part of a highly selective strategy.
Panellists will look into this seeming resurgence of M&A and its implications for early-stage deals, discussing funding availability, business development prospects and deal pattern observations.